Medication-related AI can help detect potential adverse drug reactions by analysing medication histories, clinical notes, laboratory results, symptoms, and treatment timelines.
However, a major technical challenge remains: distinguishing a genuine medication-related event from a coincidental clinical occurrence.
Consider a patient who develops nausea after starting a new medication. A machine learning model may identify a strong association between the drug and the symptom. Yet the patient could have an underlying gastrointestinal condition, an infection, or another medication contributing to the event.
A robust medication safety pipeline should therefore go beyond simple co-occurrence detection.
It should establish medication exposure and timing, examine dosage and possible interactions, incorporate relevant patient characteristics, identify competing explanations, and communicate the confidence and limitations of its findings.
This also requires careful handling of observational data. Confounding by indication, reporting bias, incomplete medication histories, and inconsistent clinical documentation can all distort the relationship between a drug and an observed outcome.
AI can support pharmacovigilance through signal detection, case prioritisation, pattern discovery, and explainable risk assessment. However, a detected signal should remain a signal until appropriately investigated.
For agentic AI, the architecture needs an additional safety layer. Detecting a suspected adverse event should not automatically authorise treatment modification. Systems need clearly defined permissions, escalation pathways, human approval where appropriate, and auditable records of their recommendations and actions.
The engineering objective should be to build systems that recognise possible harm while remaining honest about what the evidence can establish.
If you are developing medication safety, pharmacovigilance, or healthcare AI systems, prioritise causality-aware reasoning and clinically governed escalation in your design.
